BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai 10th People's Hospital
About this trial
To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.
Eligibility criteria
Qualifiers
Adult patients (>18 years old);
Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization;
Patients must have received in-hospital CEM for at least 5 days;
Patients must give informed consent.
Disqualifiers
Patients with a medical history of pre-existing AF;
Patients with a medical history of rheumatic valvular disease;
Patients with a medical history of sick sinus syndrome;
Patients undergoing emergent coronary artery bypass surgery;
Trial design
Treatments tested in this trial
- Continuous Electronic Monitor
Treatment groups
774 Participants
are divided into 2 treatment groupsSponsors and collaborators
Shanghai 10th People's Hospital
Lead sponsor
Shanghai Tong Ren Hospital
Collaborator
Kaifeng Central Hospital
Collaborator
Shanghai 7th People's Hospital
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
Luoyang Central Hospital
Collaborator
Source ClinicalTrials.gov